Differential Importance of Glucose-Dependent Insulinotropic Polypeptide vs Glucagon-Like Peptide 1 Receptor Signaling for Beta Cell Survival in Mice

Gastroenterology

Volumn 137, Issue 6, 2009, Pages 2146-2157

  Maida, Adriano ^a   Hansotia, Tanya ^a   Longuet, Christine ^a   Seino, Yutaka ^b   Drucker, Daniel J ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

^b KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; HEMOGLOBIN A1C; INCRETIN; INSULIN; SITAGLIPTIN; STREPTOZOCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CELL PROTECTION; CELL REGENERATION; CELL SURVIVAL; CONTROLLED STUDY; GENE EXPRESSION PROFILING; GLUCOSE BLOOD LEVEL; INSULIN BLOOD LEVEL; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; STREPTOZOCIN DIABETES;

EID: 70649094346     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2009.09.004     Document Type: Article

References (44)

1. Drucker D.J. The role of gut hormones in glucose homeostasis. J Clin Invest 117 (2007) 24-32
2. Mayo K.E., Miller L.J., Bataille D., et al. International Union of Pharmacology. XXXV. The glucagon receptor family. Pharmacol Rev 55 (2003) 167-194
3. Hansotia T., Maida A., Flock G., et al. Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure. J Clin Invest 117 (2007) 143-152
4. Kim S.J., Nian C., and McIntosh C.H. Resistin is a key mediator of glucose-dependent insulinotropic polypeptide (GIP) stimulation of lipoprotein lipase (LPL) activity in adipocytes. J Biol Chem 282 (2007) 34139-34147
5. Miyawaki K., Yamada Y., Ban N., et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med 8 (2002) 738-742
6. McClean P.L., Irwin N., Cassidy R.S., et al. GIP receptor antagonism reverses obesity, insulin resistance and associated metabolic disturbances induced in mice by prolonged consumption of high fat diet. Am J Physiol Endocrinol Metab 293 (2007) E1746-E1755
7. Deacon C.F. Therapeutic strategies based on glucagon-like peptide 1. Diabetes 53 (2004) 2181-2189
8. Drucker D.J. The biology of incretin hormones. Cell Metab 3 (2006) 153-165
9. Holz G.Gt., Kuhtreiber W.M., and Habener J.F. Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37). Nature 361 (1993) 362-365
10. Stoffers D.A., Kieffer T.J., Hussain M.A., et al. Insulinotropic glucagon-like peptide-1 agonists stimulate expression of homeodomain protein IDX-1 and increase b-cell mass in mouse pancreas. Diabetes 49 (2000) 741-748
11. Xu G., Stoffers D.A., Habener J.F., et al. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48 (1999) 2270-2276
12. Farilla L., Hui H., Bertolotto C., et al. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 143 (2002) 4397-4408
13. Farilla L., Bulotta A., Hirshberg B., et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 144 (2003) 5149-5158
14. Wang Q., and Brubaker P.L. Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice. Diabetologia 45 (2002) 1263-1273
15. Li Y., Hansotia T., Yusta B., et al. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem 278 (2003) 471-478
16. Ling Z., Wu D., Zambre Y., et al. Glucagon-like peptide 1 receptor signaling influences topography of islet cells in mice. Virchows Arch 438 (2001) 382-387
17. Trumper A., Trumper K., and Horsch D. Mechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in beta(INS-1)-cells. J Endocrinol 174 (2002) 233-246
18. Trumper A., Trumper K., Trusheim H., et al. Glucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signaling. Mol Endocrinol 15 (2001) 1559-1570
19. Kim S.J., Winter K., Nian C., et al. GIP stimulation of pancreatic beta-cell survival is dependent upon phosphatidylinositol 3-kinase (PI3-K)/ protein kinase B (PKB) signaling, inactivation of the forkhead transcription factor Foxo1 and downregulation of bax expression. J Biol Chem 280 (2005) 22297-22307
20. Pamir N., Lynn F.C., Buchan A.M., et al. Glucose-dependent insulinotropic polypeptide receptor null mice exhibit compensatory changes in the enteroinsular axis. Am J Physiol Endocrinol Metab 284 (2003) E931-E939
21. Hansotia T., Baggio L.L., Delmeire D., et al. Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors. Diabetes 53 (2004) 1326-1335
22. Lamont B.J., and Drucker D.J. Differential anti-diabetic efficacy of incretin agonists vs. DPP-4 inhibition in high fat fed mice. Diabetes 57 (2008) 190-198
23. Maida A., Lovshin J.A., Baggio L.L., et al. The glucagon-like peptide-1 receptor agonist oxyntomodulin enhances {beta}-cell function but does not inhibit gastric emptying in mice. Endocrinology 149 (2008) 5670-5678
24. Villhauer E.B., Brinkman J.A., Naderi G.B., et al. 1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem 46 (2003) 2774-2789
25. Hinke S.A., Gelling R.W., Pederson R.A., et al. Dipeptidyl peptidase IV-resistant [D-Ala(2)]glucose-dependent insulinotropic polypeptide (GIP) improves glucose tolerance in normal and obese diabetic rats. Diabetes 51 (2002) 652-661
26. Kuhn-Wache K., Manhart S., Hoffmann T., et al. Analogs of glucose-dependent insulinotropic polypeptide with increased dipeptidyl peptidase IV resistance. Adv Exp Med Biol 477 (2000) 187-195
27. Pieper A.A., Brat D.J., Krug D.K., et al. Poly(ADP-ribose) polymerase-deficient mice are protected from streptozotocin-induced diabetes. Proc Natl Acad Sci U S A 96 (1999) 3059-3064
28. Rhodes C.J. Type 2 diabetes-a matter of beta-cell life and death?. Science 307 (2005) 380-384
29. Vilsboll T., Krarup T., Madsbad S., et al. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia 45 (2002) 1111-1119
30. Vilsboll T., Knop F.K., Krarup T., et al. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype. J Clin Endocrinol Metab 88 (2003) 4897-4903
31. Rankin M.M., and Kushner J.A. Adaptive beta cell proliferation is severely restricted with advanced age. Diabetes 58 (2009) 1365-1372
32. Tschen S.I., Dhawan S., Gurlo T., et al. Age-dependent decline in beta cell proliferation restricts the capacity of beta cell regeneration in mice. Diabetes 58 (2009) 1312-1320
33. Kim S.J., Nian C., Widenmaier S., et al. Glucose-dependent insulinotropic polypeptide-mediated up-regulation of beta-cell antiapoptotic Bcl-2 gene expression is coordinated by cyclic AMP (cAMP) response element binding protein (CREB) and cAMP-responsive CREB coactivator 2. Mol Cell Biol 28 (2008) 1644-1656
34. Ehses J.A., Casilla V.R., Doty T., et al. Glucose-dependent insulinotropic polypeptide promotes beta-(INS-1) cell survival via cyclic adenosine monophosphate-mediated caspase-3 inhibition and regulation of p38 mitogen-activated protein kinase. Endocrinology 144 (2003) 4433-4445
35. Pederson R.A., Satkunarajah M., McIntosh C.H., et al. Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor -/- mice. Diabetes 47 (1998) 1046-1052
36. Buteau J., Foisy S., Joly E., et al. Glucagon-like peptide 1 induces pancreatic beta-cell proliferation via transactivation of the epidermal growth factor receptor. Diabetes 52 (2003) 124-132
37. MacDonald P.E., Wang X., Xia F., et al. Antagonism of rat beta-cell voltage-dependent K+ currents by exendin 4 requires dual activation of the cAMP/protein kinase A and phosphatidylinositol 3-kinase signaling pathways. J Biol Chem 278 (2003) 52446-52453
38. Park S., Dong X., Fisher T.L., et al. Exendin-4 uses Irs2 signaling to mediate pancreatic beta cell growth and function. J Biol Chem 281 (2006) 1159-1168
39. Brubaker P.L., and Drucker D.J. Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut and central nervous system. Endocrinology 145 (2004) 2653-2659
40. Ahren B., Winzell M.S., Wierup N., et al. DPP-4 inhibition improves glucose tolerance and increases insulin and GLP-1 responses to gastric glucose in association with normalized islet topography in mice with beta-cell-specific overexpression of human islet amyloid polypeptide. Regul Pept 143 (2007) 97-103
41. Mu J., Woods J., Zhou Y.P., et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic β-cell mass and function in a rodent model of type 2 diabetes. Diabetes 55 (2006) 1695-1704
42. Flock G., Baggio L.L., Longuet C., et al. Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice. Diabetes 56 (2007) 3006-3013
43. Kim S.J., Nian C., Doudet D.J., et al. Inhibition of dipeptidyl peptidase IV with sitagliptin (MK0431) prolongs islet graft survival in streptozotocin-induced diabetic mice. Diabetes 57 (2008) 1331-1339
44. Pospisilik J.A., Martin J., Doty T., et al. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes 52 (2003) 741-750